Equities analysts forecast that Medpace Holdings Inc (NASDAQ:MEDP) will announce sales of $184.86 million for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Medpace’s earnings, with the highest sales estimate coming in at $188.00 million and the lowest estimate coming in at $183.00 million. Medpace reported sales of $112.68 million during the same quarter last year, which indicates a positive year-over-year growth rate of 64.1%. The firm is scheduled to announce its next quarterly earnings report on Monday, February 25th.

According to Zacks, analysts expect that Medpace will report full-year sales of $697.31 million for the current fiscal year, with estimates ranging from $695.47 million to $700.40 million. For the next financial year, analysts expect that the company will post sales of $797.65 million, with estimates ranging from $782.70 million to $808.29 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Medpace.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Thursday, November 1st. The company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.63 by $0.04. The company had revenue of $179.00 million during the quarter, compared to the consensus estimate of $175.07 million. Medpace had a net margin of 10.84% and a return on equity of 15.86%. The firm’s revenue for the quarter was up 44.4% compared to the same quarter last year. During the same period last year, the firm earned $0.40 EPS.

A number of equities analysts have recently commented on MEDP shares. William Blair raised shares of Medpace from a “market perform” rating to an “outperform” rating in a report on Tuesday, July 31st. BidaskClub downgraded shares of Medpace from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 31st. Credit Suisse Group raised their price objective on shares of Medpace from $42.00 to $49.00 and gave the stock an “outperform” rating in a report on Tuesday, July 31st. Zacks Investment Research raised shares of Medpace from a “hold” rating to a “strong-buy” rating and set a $69.00 price objective for the company in a report on Friday, August 3rd. Finally, TheStreet raised shares of Medpace from a “c” rating to a “b-” rating in a report on Friday, August 10th. Four investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Medpace presently has a consensus rating of “Buy” and an average price target of $44.43.

Shares of NASDAQ:MEDP traded down $1.66 during midday trading on Friday, reaching $55.68. 542,510 shares of the company’s stock were exchanged, compared to its average volume of 442,114. The company has a market capitalization of $2.06 billion, a price-to-earnings ratio of 36.63, a PEG ratio of 1.44 and a beta of 1.41. Medpace has a 12 month low of $31.70 and a 12 month high of $65.09. The company has a debt-to-equity ratio of 0.25, a quick ratio of 0.66 and a current ratio of 0.66.

In related news, major shareholder Medpace Investors, Llc sold 61,141 shares of the stock in a transaction dated Wednesday, September 19th. The shares were sold at an average price of $60.20, for a total transaction of $3,680,688.20. Following the completion of the sale, the insider now owns 9,084,369 shares in the company, valued at approximately $546,879,013.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Medpace Limited Partnership sold 5,224,997 shares of the stock in a transaction dated Monday, August 27th. The stock was sold at an average price of $54.75, for a total transaction of $286,068,585.75. The disclosure for this sale can be found here. Insiders have sold a total of 5,621,556 shares of company stock valued at $309,490,974 in the last quarter. 29.50% of the stock is currently owned by corporate insiders.

Several institutional investors have recently made changes to their positions in MEDP. Laurion Capital Management LP acquired a new stake in shares of Medpace during the 2nd quarter worth about $29,230,000. BlackRock Inc. increased its position in shares of Medpace by 42.1% during the 3rd quarter. BlackRock Inc. now owns 2,282,063 shares of the company’s stock worth $136,719,000 after purchasing an additional 676,396 shares in the last quarter. Fuller & Thaler Asset Management Inc. acquired a new stake in shares of Medpace during the 3rd quarter worth about $37,292,000. Renaissance Technologies LLC increased its position in shares of Medpace by 131.6% during the 3rd quarter. Renaissance Technologies LLC now owns 784,900 shares of the company’s stock worth $47,023,000 after purchasing an additional 446,000 shares in the last quarter. Finally, Deutsche Bank AG increased its position in shares of Medpace by 472.2% during the 3rd quarter. Deutsche Bank AG now owns 509,957 shares of the company’s stock worth $30,550,000 after purchasing an additional 420,833 shares in the last quarter. Institutional investors and hedge funds own 42.40% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Further Reading: Technical Analysis of Stocks, How Can It Help

Get a free copy of the Zacks research report on Medpace (MEDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.